Abstract
The expression of proliferating cell nuclear antigen (PCNA) was examined in formalin-fixed paraffin-embedded tissue sections from 41 lesions (27 melanocytic nevi, 3 atypical nevi and 11 malignant melanomas) to determine the proliferative activity of primary cutaneous melanocytic tumours. Most of the malignant melanomas had more than 7% PCNA-positive cells (9.2±0.5%), while the melanocytic nevi manifested less than 1% PCNA-positive cells (0.4±0.1%). Atypical nevi exhibited an intermediate, but still significantly lower, labelling ratio when compared with malignant melanomas (0.8±0.2%). The proliferative activity of the lesions was compared between portions at different depths in the skin (epidermal, upper dermal and lower dermal location). In cases of malignant melanoma, the proliferative activity was higher in the deeper portion of dermis whereas PCNA-positive cells in melanocytic nevi were located in the upper dermis predominantly. Thus the PCNA labelling ratio of malignant melanoma and/or melanocytic nevus cells located in the epidermodermal junction was not necessarily higher than that of malignant melanoma and/or melanocytic nevus cells in the dermis. These results indicate that staining with PCNA would be very useful in the differentiation of malignant melanoma from melanocytic nevi manifesting cellular and/or structural atypia by virtue of a significant difference in the proportion of PCNA-positive cells. Although malignant melanomas have higher proliferative activity than melanocytic nevi in the deeper dermis, junctional activity in melanocytic tumours does not indicate cell proliferation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ackerman AB (1980) Malignant melanoma: a unifying concept. Hum Pathol 11:591–595
Ackerman AB, David KM (1986) A unifying concept of malignant melanoma: biologic aspects. Hum Pathol 17:438–440
Ackerman AB, Mihara I (1985) Dysplasia, dysplastic melanocytes, dysplastic nevi, dysplastic nevus syndrome, and the malignant melanomas. Hum Pathol 16:87–91
Almendri MJ, Huebsch D, Blundell AP, Macdonald-Bravo H, Bravo R (1987) Cloning and sequence of the human nuclear protein cyclin: homology with DNA-binding proteins. Proc Natl Acad Sci USA 84:1575–1579
Bentley-Phillips C, Marks R (1976) Cell division and metabolic activity of naevus cells. Br J Dermatopathol 94:557–563
Bravo R, Frank R, Blundell PA, Macdonald-Bravo H (1987) Cyclin/PCNA is the auxiliary protein of DNA polymerase-δ. Nature 326:515–517
Breslow A (1975) Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma. Ann Surg 182:572–575
Clark WH Jr, From L, Bernardino EA, Mihm MC (1969) The histogenesis and biologic behavior of primary human malignant melanoma of the skin. Cancer Res 29:705–726
Clark WH Jr, Elder DE, Guerry D, Epstein MN, Green MH, Horn MV (1984) A study of tumor progression. Hum Pathol 15:1147–1165
Clemente C, Cochran AJ, Elder DE, Levene A, Mackie RM, Mihm MC Jr, Rilke F, Cascinelli N, Fitzpatrick TB, Sober AJ (1991) Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the world health organization melanoma programme. Hum Pathol 22:313–319
Ellison DJ, Nathwani BN, Metter GE, Turner RR, Burke JS, Miller TP, Mann RB, Barcos M, Kjeldsberg CR, Winberg CD, Whitcomb CC (1987) Mitotic counts in follicular lymphomas. Hum Pathol 18:502–505
Garcia RL, Coltrera MD, Grown AM (1989) Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Am J Pathol 134:733–739
Giorno R (1984) A comparison of two immunoperoxidase staining methods based on the avidin-biotin interaction. Diagn Immunol 2:161–166
Hall PA, Levinson DA (1990) Assessment of cell proliferation in histological material. J Clin Pathol 43:184–192
Hall PA, Levison DA, Woods AL, Yu CCW, Kellock DB, Watkins JA, Barnes DM, Gillett CE, Camplejohn R, Dover R, Waseem NH, Lane DP (1990) Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections. J Pathol 162:285–294
Kaudewitz P, Braun-Falco O, Ernst M, Landthaler M, Stoltz W, Gerdes J (1989) Tumor cell growth fractions in human malignant melanomas and correlation to histopathologic tumor grading. Am J Pathol 134:1063–1068
Kopf AW, Gross DF, Rogers GS, Rigel DS, Hellman LJ, Levenstein M, Welkovich B, Friedman RJ, Roses DF, Bart RS, Mintzis MM, Gumport SL (1987) Prognostic index for malignant melanoma. Cancer 59:1236–1241
McGovern VJ, Mihm MC, Bailly C, Booth JC, Clark WH, Cochran AJ, Hardy EG, Hicks JD, Levene A, Lewis MG, Little JH, Milton GW (1973) The classification of malignant melanoma and its histologic reporting. Cancer 32:1446–1457
McGurrin JF, Doria MI, Dawson PJ, Karrison T, Stein HO, Franklin WA (1987) Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast. Cancer 59:1744–1750
Miyachi K, Fritzler MJ, Tan EM (1978) Autoantibody to a nuclear antigen in proliferating cells. J Immunol 121:2228–2234
Moretti S, Massobrio R, Brogelli L, Novelli M, Giannotti B, Bernengo MG (1990) Ki67 antigen expression correlates with tumor progression and HLA-DR antigen expression in melanocytic lesions. J Invest Dermatol 95:320–324
Morris GF, Mathews MB (1989) Regulation of proliferating cell nuclear antigen during the cell cycle. J Biol Chem 264:13856–13864
Ogata K, Kurki P, Celis JE, Nakamura RM, Tan EM (1987) Monoclonal antibodies to a nuclear protein (PCNA/Cyclin) associated with DNA replication. Exp Cell Res 168:475–486
Prelich G, Tan C, Kostura M, Mathews MB, So AG, Downey KM, Stillman B (1987) Functional identity of proliferating cell nuclear antigen and a DNA polymerase-δ auxilliary protein. Nature 326:517–518
Quinn CM, Wright NA (1990) The clinical assessment of proliferation and growth in human tumours. J Pathol 160:93–102
Schmoeckel C, Braun-Falco O (1978) Prognostic index in malignant melanoma. Arch Dermatol 114:871–873
Shirakawa S, Luce JK, Tannock I, Feri E III (1970) Cell proliferation in human melanoma. J Clin Invest 49:1188–1199
Smolle J, Soyer H-P, Kerl H (1989) Proliferative activity of cutaneous melanocytic tumors defined by Ki-67 monoclonal antibody. Am J Dermatopathol 11:301–307
Takahashi H, Strutton GM, Parsons PG (1991) Determination of proliferating fractions in malignant melanomas by anti-PCNA/cyclin monoclonal antibody. Histopathology 18:221–227
Urso C, Bondi R, Balzi M, Sculba E, Mauri P, Becciolini A, Tarocchi S, Vallecchi C (1992) Cell kinetics of melanocytes in common and dysplastic nevi and in primary and metastatic cutaneous melanoma. Pathol Res Pract 188:323–329
Worth AJ, Gallagher RP, Elwood JM, Yang PC, Lamb C, Spinelli JJ, Wood WS, Threlfall WJ, Hill GB (1989) Pathologic prognostic factors for cutaneous malignant melanoma. Int J Cancer 43:370–375
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kuwata, T., Kitagawa, M. & Kasuga, T. Proliferative activity of primary cutaneous melanocytic tumours. Vichows Archiv A Pathol Anat 423, 359–364 (1993). https://doi.org/10.1007/BF01607148
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01607148